Ocuphire Pharma Investor Day Presentation Deck
P
Efficacy Signal
Percent of subjects with 23-line improvement in
near vision with less than 5 letters of distance
loss in Nyxol+LDP combo compared to Nyxol
alone and LDP alone as demonstrated in
well-controlled, multi-center clinical trials
What's Important?
Nyxol+LDP has the Potential to be "Best in Class" Presbyopia Eyedrop
Safety
No loss of distance (included in efficacy)
Maintain night distance vision
Well-tolerated
Broad Label Opportunity
For VuityTM, FDA did not limit the use of the
product to clinical trial parameters such as:
●
88
age
lighting conditions (photopic or mesopic)
monocular or binocular
phakic status
Vuity Label 2021
FDA
Guidance
Physician/
Patients
Efficacy Signal
Achieve "functional near vision" and
intermediate vision
Achieve optimal pupil size
Durability
Dynamic/responsive pupil
●
●
Safety
No loss of distance vision
No headaches or brow aches
Reliable night distance vision
No stinging or burning
Minimal redness
Patient Experience
Tunability - ability to customize treatment
based on patient's lifestyle needs
Favorable tolerability for continued use and
Rx refills
Ocuphire
PHARMAView entire presentation